ARTESIA Trial Summary The ARTESIA trial, which stands for “Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation,” was a landmark study aimed at comparing the efficacy and safety of apixaban versus aspirin in patients with subclinical atrial fibrillation (AF). The … Read More
apixaban
ELAN Trial: Early vs. Later Initiation of DOAC in Acute Ischemic Stroke and Atrial Fibrillation
ELAN Trial Summary Introduction:The ELAN trial aimed to investigate the optimal timing of initiating direct oral anticoagulants (DOACs) in individuals with atrial fibrillation (AF) who had experienced an acute ischemic stroke. The study compared early anticoagulation (initiated within 48 hours … Read More
Navigating the New Era: Landmark Clinical Trials on Eliquis (Apixaban) for Anticoagulation in Atrial Fibrillation
Atrial fibrillation (AFib) is a prevalent cardiac arrhythmia that significantly elevates the risk of stroke and systemic embolism. As a result, effective anticoagulation therapy is crucial for managing AFib patients. Over the past decade, novel oral anticoagulants (NOACs) have challenged … Read More
AMPLIFY Trial: Apixaban for acute VTE
2013 AMPLIFY TRIAL Oral Apixaban for the Treatment of Acute Venous Thromboembolism double-blind, multicenter, randomized controlled trial IM Objective: To determine if apixaban is non-inferior to conventional therapy with LMWH in patients with pulmonary embolism or proximal deep venous thrombosis … Read More
ADAM VTE Trial Summary: Apixaban in Cancer-associated VTE
2019 ADAM VTE TRIAL Apixaban and dalteparin in active malignancy-associated venous thromboembolism multicenter, randomized, open-label superiority trial 287 patients 0 Objective: To study side effects of and compare apixaban and dalteparin in reducing blood clots in patients with cancer-related VTE. … Read More